Full Press Release Details
Announces $1 Million Share Buyback Program
ORLANDO, Fla., Sept 16, 2024 - Nutriband Inc. (NASDAQ: NTRB)
(NASDAQ: NTRBW), has announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of September 16, 2024,
the Company had 11,106,185 shares of common stock outstanding.
Progress continues on the development of AVERSA Fentanyl, with the
Company maintaining its target of submitting an NDA to the FDA in Q1/Q2 2025
About Nutriband Inc.
We are primarily engaged in
the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent
fentanyl patch incorporating our AVERSA abuse deterrence technology. AVERSA technology can be incorporated into any
transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com.
Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without
limitation, statements containing the words "believes," "anticipates," "expects" and words of similar import,
constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated
in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed
abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology,
its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal
Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval
necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its
ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business
strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic
and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under
"Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the
Company's Form S-1, Form 10-K for the year ended January 31, 2024 and Forms 10-Q, and the Company's other filings with the Securities
and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements
to reflect any event or circumstance that may arise after the date hereof.
For more information, contact:
RedChip Companies, Inc.
Email: NTRB@Redchip.com
Phone: 1-407-644-4256
431 E Horatio Ave, Suite #100